Milestone Scientific Inc. Announces Breakthrough CompuPulse System and Receives Notice of Allowance for U.S. Patent
February 24 2021 - 3:15PM
Milestone Scientific Inc. (NYSE American:MLSS), a
leading developer of computerized drug delivery instruments that
provides virtually painless and precise injections, today announced
that it has received a Notice of Allowance from the United States
Patent and Trademark Office (USPTO) related to its new CompuPulse
System, which integrates the Company’s CompuWave™ technology with a
manual syringe.
Mark Hochman, D.D.S., Inventor and Clinical
Director for Milestone Scientific, commented, "We are pleased to
receive this Notice of Allowance related to our new CompuPulse
System, which combines the benefits of our CompuWave technology
with a manual syringe. Importantly, the new CompuPulse System
allows one to identify a pulsatile pressure waveform in a variety
of applications, thereby improving the reliability and safety of a
drug delivery procedure. Importantly, not all procedures require
the sophistication of our CompuFlo system, which precisely controls
the administration and flow rate of medication as it is being
administered. This new technology provides an efficient and low
cost alternative for procedures where a manual syringe may suffice,
while still providing the ability to verify needle and subsequent
catheter placement.”
Leonard Osser, Interim Chief Executive Officer of
Milestone Scientific, stated, “This Notice of Allowance
significantly expands the intellectual property surrounding our
injection and drug delivery systems and, in turn, further
solidifies our leadership position in the computerized injection
market. We believe that the combination of the CompuWave technology
with the lower cost of a manual syringe opens up a number of
exciting new markets and applications for our technology, while
still ensuring precise confirmation of needle placement and
verification that a catheter has not been displaced during or after
a procedure.”
The Notice of Allowance relates to a method and an
apparatus that detects a pulsatile pressure waveform to more easily
perform the identification of anatomical target regions. The
pulsatile waveform is representative of the detection of pressures
that are produced by the cardio-vascular system either directly or
indirectly. This same system can be used to aid in the
determination of the patency of a catheter and to assist in
determining if a catheter has been displaced during a
procedure.
About Milestone Scientific
Inc.
Milestone Scientific Inc. (MLSS) is a biomedical
technology research and development company that patents, designs
and develops innovative diagnostic and therapeutic injection
technologies and instruments for medical, dental, cosmetic and
veterinary applications. Milestone's computer-controlled systems
are designed to make injections precise, efficient, and virtually
painless. Milestone’s proprietary DPS Dynamic Pressure Sensing
technology® is our technology platform that advances the
development of next-generation devices, regulating flow rate and
monitoring pressure from the tip of the needle, through platform
extensions for local anesthesia for subcutaneous drug delivery,
with specific applications for cosmetic botulinum toxin injections,
epidural space identification in regional anesthesia procedures and
intra-articular joint injections. For more information please visit
our website: www.milestonescientific.com.
Safe Harbor Statement
This press release contains forward-looking
statements regarding the timing and financial impact of Milestone's
ability to implement its business plan, expected revenues, timing
of regulatory approvals and future success. These statements
involve a number of risks and uncertainties and are based on
assumptions involving judgments with respect to future economic,
competitive and market conditions, future business decisions and
regulatory developments, all of which are difficult or impossible
to predict accurately and many of which are beyond Milestone's
control. Some of the important factors that could cause actual
results to differ materially from those indicated by the
forward-looking statements are general economic conditions, failure
to achieve expected revenue growth, changes in our operating
expenses, adverse patent rulings, FDA or legal developments,
competitive pressures, changes in customer and market requirements
and standards, and the risk factors detailed from time to time in
Milestone's periodic filings with the Securities and Exchange
Commission, including without limitation, Milestone's Annual Report
for the year ended December 31, 2019. The forward-looking
statements in this press release are based upon management's
reasonable belief as of the date hereof. Milestone undertakes no
obligation to revise or update publicly any forward-looking
statements for any reason.
Contact:David Waldman or Natalya
RudmanCrescendo Communications, LLCEmail: mlss@crescendo-ir.comTel:
212-671-1020
Milestone Scientific (AMEX:MLSS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Milestone Scientific (AMEX:MLSS)
Historical Stock Chart
From Sep 2023 to Sep 2024